All SHP News News February 9, 2022

Chronic Kidney Disease Now Has Powerful, Cost-Effective Treatment

Chronic kidney disease affects one-in-seven adults and is the ninth leading cause of death in the United States. A new Stanford-led study now provides clinicians with a powerful, cost-effective treatment for their patients with renal disease.
Illustration of kidneys
Getty Images

Clinicians know the drug dapagliflozin helps patients with chronic kidney disease that stems from diabetes. New Stanford-led research now shows the drug is also a powerful, cost-effective treatment in those who suffer from CKD even if their disease is not caused by diabetes.

An estimated one-in-seven adults in the United States suffer from chronic kidney disease, with an annual $100 billion in health-care costs. The condition means kidneys don’t properly filter impurities from the blood, which can lead to a buildup of waste in the body and an increased risk of cardiovascular disease, impaired physical and cognitive function and overall reduced quality of life.

“Since a huge number of Americans have chronic kidney disease, this treatment could improve quality of life and longevity for many thousands of people, so finding that it is 'worth it' cost-wise is really important for justifying its use,” said SHP’s Rebecca L. Tisdale, MD, MPA, co-lead author of the study published in the Journal of General Internal Medicine. The other co-lead author is Marika Cusick, a PhD student at Stanford Health Policy. 

"Clinicians may be hesitant to prescribe a new drug without research demonstrating that it produces reasonable benefits for the cost — and this finding can provide some of that reassurance," Tisdale said

Stanford Health Policy Director Douglas K. Owens, senior author of the study, said the team conducted a model-based cost-effectiveness analysis and found that dapagliflozin provides an important new tool for patients with chronic kidney disease, the ninth leading cause of death in the United States.

These numbers further illustrate the complexity of care for CKD, and we are delighted to have found a cost-effective treatment option.'
Marika Cusick
PhD student at Stanford Health Policy

Tisdale, an internist and postdoctoral research fellow with Stanford Health Policy and the Palo Alto VA, explained that the researchers evaluated the cost-effectiveness of adding dapagliflozin to the existing standard care of treatment, one of two closely related classes of drugs, ACE inhibitors or ARBs.

The team found that adding dapagliflozin to standard care improved life expectancy by two years. The new treatment would increase lifetime costs by $60,000 per QALY (quality-adjusted life years), which is considered a reasonable additional price to pay for living longer and decreases in the need for kidney transplant and dialysis treatment.

While CKD affects about 12.5% of Medicare beneficiaries, it is responsible for a disproportionate 23% of expenditures even before accounting for enrollees with end-stage kidney disease.

“These numbers further illustrate the complexity of care for CKD, and we are delighted to have found a cost-effective treatment option,” said Cusick.

The other co-authors of the study are Kelly Zhang Aluri, Thomas J. Handley, Alice Kate Cummings Joyner, Joshua A. Salomon, Glenn M. Chertow, and Jeremy Goldhaber-Fiebert.

Rebecca Tisdale, MD, MPA

Postdoctoral Research Fellow
An internist who focuses on global health cardiology and health systems.
Rebecca Tisdale Stanford

Marika Cusick, MS

PhD student in Health Policy
Researches cost-effective and equitable chronic disease management.
Marika Cusick Stanford Health Policy

read more

An illustration of opioid addiction.
News

Stanford Team Reveals Cost-Effective and Life-Saving Treatment for Nation's Opioid Disorder Epidemic

A Stanford team of decision scientists with colleagues at the VA Palo Alto Health Care System developed a mathematical model to assess the cost-effectiveness of various interventions to treat opioid use disorder. They looked at the cost-effectiveness from two perspectives: the health-care sector and the criminal justice system.
Insulin
News

Health Experts Recommend Diabetes Screenings at 35 as Obesity Climbs

Health experts are now recommending that clinicians begin screening patients for prediabetes and type 2 diabetes at age 35.
An illustration of balancing health-care costs
News

Improving the Performance of Health Plan Payment Systems

Sherri Rose illustrates ways to improve payments to health-care plans, making them more efficiently and fairly distributed.